Blood advances

Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy.

Blood advances

Ananth S, Torres NE, Sahaf B, Mikkilineni L, Fernandez-Pol S, Salmi D, Negrin RS, Shiraz P, Smith M, Bharadwaj S, Weng WK, Kennedy VE, Dahiya S, Muffly LS, Miklos DB, Frank MJ, Hosoya H, Sidana S

Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy.

Blood advances

Lust H, Schultz LM, Kwon S, Roloff GW, Aldoss I, Baggott C, John S, Rossoff J, McNerney KO, Fabrizio VA, Talano JA, Moskop A, Curran KJ, Phillips CL, Karras NA, Baumeister SHC, Cooper S, Hermiston ML, Satwani P, Qayed M, Raikar SS, MacMillan ML, Hall EM, Nguyen K, Cassaday RD, Kopmar NE, Kota VK, Mathews J, Shaughnessy PJ, Schwartz MS, Ladha A, Yaghmour G, Kumaran M, Bachanova V, Tracy SI, Othman T, Luskin MR, Chen EC, Advani AS, Jeyakumar N, Miller K, Zhang A, Shah BD, Muffly LS, Faramand RG

Beat-AML 2024 ELN-Refined Risk Stratification for Older Adults with Newly Diagnosed AML Given Lower-Intensity Therapy.

Blood advances

Hoff FW, Blum W, Huang Y, Welkie RL, Swords R, Traer E, Stein EM, Lin TL, Archer KJ, Patel PA, Collins RH, Baer MR, Duong VH, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics TJ, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran E, Koenig KL, Heerema NA, Chen TL, Martycz M, Stefanos M, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate U, Mims AS, Byrd JC, Madanat YF

In Utero Hematopoietic Stem Cell Transplantation for Fanconi Anemia.

Blood advances

Swartzrock L, Dib C, Denis M, Willner H, Ho K, Haslett E, Han J, Pan W, Byrne-Steele M, Brown B, Krampf MR, Girsen A, Blumenfeld YJ, El-Sayed YY, Roncarolo MGG, MacKenzie TC, Czechowicz AD

A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.

Blood advances

Levis MJ, Perl AE, Schiller GJ, Fathi AT, Roboz GJ, Wang ES, Altman JK, Rajkhowa T, Ando M, Suzuki T, Subach RA, Maier G, Madden T, Johansen M, Cheung K, Kurman M, Smith CC

Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.

Blood advances

Chandrakasan S, Jordan MB, Baker A, Behrens EM, Bhatla D, Chien M, Eckstein OS, Henry MM, Hermiston ML, Hinson A, Leiding JW, Oladapo A, Patel SA, Pednekar P, Ray A, Dávila Saldaña BJ, Sarangi SN, Walkovich K, Yee JD, Zoref-Lorenz A, Allen CE

ANHL1522: Durable Immunity to EBV post Rituximab and Third Party LMP-specific T-cells: A Children's Oncology Group Study.

Blood advances

Wistinghausen B, Toner K, Barkauskas DA, Jerkins LP, Kinoshita H, Chansky P, Pezzella G, Saguilig L, Hayashi RJ, Abhyankar HA, Scull B, Karri V, Tanna J, Hanley PJ, Hermiston ML, Allen CE, Bollard CM

Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL.

Blood advances

Levinson AL, Tjoa K, Huang B, Meyer LK, Kim MO, Brady SW, Zhang J, Shannon K, Wandler AM

Histone deacetylase-6 modulates the effects of 4°C platelets on vascular endothelial permeability.

Blood advances

Miyazawa B, Trivedi A, Vivona L, Lin M, Potter D, Nair A, Barry M, Cap AP, Pati S

Opposing Effects of KDM6A and JDP2 on Glucocorticoid Sensitivity in T-ALL

Blood advances

Levinson A, Tjoa K, Huang BJ, Meyer LK, Kim MO, Brady SW, Zhang J, Shannon KM, Wandler A.

Pages